Attorney General Headshot

Attorney General Jason R. Ravnsborg

Attorney General Seal

Eli Lilly to Pay More Than $1.4 Billion for Off-Label Drug Marketing

Eli Lilly to Pay More Than $1.4 Billion for Off-Label Drug Marketing 

PIERRE, S.D.-  Attorney General Larry Long announced today that South Dakota has joined with other states and the federal government and reached a $1.4 billion settlement with Eli Lilly and Company, to settle allegations it engaged in an off-label marketing campaign that improperly promoted the anti-psychotic drug, Zyprexa. Eli Lilly will pay the states and the federal government a total of $800 million in damages and penalties to compensate Medicaid and various federal healthcare programs for harm suffered as a result of this conduct.  

South Dakota’s total settlement recovery is $1.4 million. Of that amount, South Dakota will keep $475,000, which represents the state’s share of the Medicaid loss, with the remainder going to the federal government for its share.

Between September 1999 and December 31, 2005, Eli Lilly willfully promoted the sale and use of Zyprexa, primarily through a marketing campaign called “Viva Zyprexa,” for certain uses which the Food and Drug Administration had not approved. The promotional activities undertaken by Eli Lilly in the “Viva Zyprexa” campaign promoted Zyprexa not only to psychiatrists, but also to primary care physicians, for such unapproved uses as the treatment of depression, anxiety, irritability, disrupted sleep, nausea and gambling addiction. In implementing the campaign, Eli Lilly also provided remuneration and other things of value to physicians and other health care professionals. As a result of these promotional activities, Eli Lilly caused physicians to prescribe Zyprexa for children and adolescents, dementia patients in long term care facilities, and in unapproved dosage amounts, all of which are uses that were not medically accepted indications for which state Medicaid programs would approve reimbursement. 

As part of the settlement, Eli Lilly will enter a Corporate Integrity Agreement with the United States Department of Health and Human Services, Office of the Inspector General which will closely monitor the company’s future marketing and sales practices.

This settlement is based on four qui tam cases that were filed or consolidated in the United States District Court for the Eastern District of Pennsylvania by various relators - private parties that filed actions under state and federal false claims statutes.

The South Dakota Medicaid Fraud Control Unit and the South Dakota Department of Social Services assisted in recovering the settlement money.